BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 29061788)

  • 1. Expression of Truncated Neurokinin-1 Receptor in Childhood Neuroblastoma is Independent of Tumor Biology and Stage.
    Pohl A; Kappler R; Mühling J; VON Schweinitz D; Berger M
    Anticancer Res; 2017 Nov; 37(11):6079-6085. PubMed ID: 29061788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-149 is associated with clinical outcome in human neuroblastoma and modulates cancer cell proliferation through Rap1 independent of MYCN amplification.
    Xu Y; Chen X; Lin L; Chen H; Yu S; Li D
    Biochimie; 2017 Aug; 139():1-8. PubMed ID: 28456710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-expression analysis identifies long noncoding RNA SNHG1 as a novel predictor for event-free survival in neuroblastoma.
    Sahu D; Hsu CL; Lin CC; Yang TW; Hsu WM; Ho SY; Juan HF; Huang HC
    Oncotarget; 2016 Sep; 7(36):58022-58037. PubMed ID: 27517149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNA N
    Cheng J; Xu L; Deng L; Xue L; Meng Q; Wei F; Wang J
    Sci Rep; 2020 Aug; 10(1):13624. PubMed ID: 32788584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting tachykinin receptors in neuroblastoma.
    Henssen AG; Odersky A; Szymansky A; Seiler M; Althoff K; Beckers A; Speleman F; Schäfers S; De Preter K; Astrahanseff K; Struck J; Schramm A; Eggert A; Bergmann A; Schulte JH
    Oncotarget; 2017 Jan; 8(1):430-443. PubMed ID: 27888795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of MYCN, DDX1, TrkA, and TrkC gene transcripts expression in neuroblastoma.
    de Souza DR; Sanabani SS; de Souza AC; Filho Odone V; Epelman S; Bendit I
    Pediatr Blood Cancer; 2011 May; 56(5):749-56. PubMed ID: 21154590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p19-INK4d inhibits neuroblastoma cell growth, induces differentiation and is hypermethylated and downregulated in MYCN-amplified neuroblastomas.
    Dreidax D; Bannert S; Henrich KO; Schröder C; Bender S; Oakes CC; Lindner S; Schulte JH; Duffy D; Schwarzl T; Saadati M; Ehemann V; Benner A; Pfister S; Fischer M; Westermann F
    Hum Mol Genet; 2014 Dec; 23(25):6826-37. PubMed ID: 25104850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Truncated neurokinin-1 receptor is an ubiquitous antitumor target in hepatoblastoma, and its expression is independent of tumor biology and stage.
    Garnier A; Ilmer M; Becker K; Häberle B; VON Schweinitz D; Kappler R; Berger M
    Oncol Lett; 2016 Jan; 11(1):870-878. PubMed ID: 26870298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features.
    Tajiri T; Liu X; Thompson PM; Tanaka S; Suita S; Zhao H; Maris JM; Prendergast GC; Hogarty MD
    Clin Cancer Res; 2003 Aug; 9(9):3345-55. PubMed ID: 12960121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PlGF and VEGF-A Regulate Growth of High-Risk MYCN-Single Copy Neuroblastoma Xenografts via Different Mechanisms.
    Zins K; Kovatchki D; Lucas T; Abraham D
    Int J Mol Sci; 2016 Sep; 17(10):. PubMed ID: 27669225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Study on MYCN gene amplification and CD44 expression in neuroblastoma].
    Hu HL; He LJ
    Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):332-6. PubMed ID: 15363318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PRC2-Mediated Transcriptomic Alterations at the Embryonic Stage Govern Tumorigenesis and Clinical Outcome in MYCN-Driven Neuroblastoma.
    Tsubota S; Kishida S; Shimamura T; Ohira M; Yamashita S; Cao D; Kiyonari S; Ushijima T; Kadomatsu K
    Cancer Res; 2017 Oct; 77(19):5259-5271. PubMed ID: 28807939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of inhibitor-of-apoptosis protein (IAP) livin by neuroblastoma cells: correlation with prognostic factors and outcome.
    Kim DK; Alvarado CS; Abramowsky CR; Gu L; Zhou M; Soe MM; Sullivan K; George B; Schemankewitz E; Findley HW
    Pediatr Dev Pathol; 2005; 8(6):621-9. PubMed ID: 16328668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High levels of polo-like kinase 1 and phosphorylated translationally controlled tumor protein indicate poor prognosis in neuroblastomas.
    Ramani P; Nash R; Sowa-Avugrah E; Rogers C
    J Neurooncol; 2015 Oct; 125(1):103-11. PubMed ID: 26318737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPAR.
    Oberthuer A; Kaderali L; Kahlert Y; Hero B; Westermann F; Berthold F; Brors B; Eils R; Fischer M
    Clin Cancer Res; 2008 Oct; 14(20):6590-601. PubMed ID: 18927300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma.
    Altungoz O; Aygun N; Tumer S; Ozer E; Olgun N; Sakizli M
    Cancer Genet Cytogenet; 2007 Jan; 172(2):113-9. PubMed ID: 17213019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma.
    Fabian J; Opitz D; Althoff K; Lodrini M; Hero B; Volland R; Beckers A; de Preter K; Decock A; Patil N; Abba M; Kopp-Schneider A; Astrahantseff K; Wünschel J; Pfeil S; Ercu M; Künkele A; Hu J; Thole T; Schweizer L; Mechtersheimer G; Carter D; Cheung BB; Popanda O; von Deimling A; Koster J; Versteeg R; Schwab M; Marshall GM; Speleman F; Erb U; Zoeller M; Allgayer H; Simon T; Fischer M; Kulozik AE; Eggert A; Witt O; Schulte JH; Deubzer HE
    Oncotarget; 2016 Oct; 7(41):66344-66359. PubMed ID: 27572323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metastatic neuroblastoma in infants: are survival rates excellent only within the stringent framework of clinical trials?
    Di Cataldo A; Agodi A; Balaguer J; Garaventa A; Barchitta M; Segura V; Bianchi M; Castel V; Castellano A; Cesaro S; Couselo JM; Cruz O; D'Angelo P; De Bernardi B; Donat J; de Andoin NG; Hernandez MI; La Spina M; Lillo M; Lopez-Almaraz R; Luksch R; Mastrangelo S; Mateos E; Molina J; Moscheo C; Mura R; Porta F; Russo G; Tondo A; Torrent M; Vetrella S; Villegas JA; Viscardi E; Zanazzo GA; Cañete A
    Clin Transl Oncol; 2017 Jan; 19(1):76-83. PubMed ID: 27041689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
    Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
    Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequent promoter hypermethylation of tachykinin-1 and tachykinin receptor type 1 is a potential biomarker for head and neck cancer.
    Misawa K; Kanazawa T; Misawa Y; Imai A; Uehara T; Mochizuki D; Endo S; Takahashi G; Mineta H
    J Cancer Res Clin Oncol; 2013 May; 139(5):879-89. PubMed ID: 23420374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.